MWIP, PPHM, BTHR, STOA & Extended Watchlist

MWIP continues to amaze us on a consistent basis. Our best medical marijuana play to date (and anyone who follows us regularly knows we’ve had some real winners!) since back in October when we began focusing intently on these things. We’ve stuck with MWIP since then, and have been duly rewarded. We’ve seen a titanic run from its November 9th low of .0024, to yesterday’s high of .042, marking a mega-move of 1650% inside of two months! Hopefully now, everyone sees why we continued to talk about marijuana-related stocks until we were green in the face!

___

Peregrine Pharmaceuticals, Inc. PPHM

PPHM is another of our recent points of focus to have a great day to open up the week on Monday. Despite gapping up 26% from its previous close, the stock still afforded us the opportunity to capitalize on a 50% intra-day gain from a low of 1.70, up to a peak of 2.55.

It appears PPHM is undergoing some course correction and filling in the large gap that we saw back in September when the stock pushed its way to the 5.50’s before falling off of a cliff.

Those who may have caught the 68-cent low in November would’ve had the chance at up to 275% in gains over the past few weeks.

___

Big Three Restaurants, Inc. BTHR

BTHR hit a high of .0036 on Monday, adding to our successful Wed-Fri. play from .0012-.0022 (83%), and presenting us the chance at max gains of up to 200% in total.

___

Sitoa Global Inc. STOA

Our inclusion of STOA on yesterday’s extended watchlist deserves a featured mention today, as the stock dipped as low as .0095 early morning, then rallied in the afternoon to hit a high of .024, before closing at .02. Savvy traders had a chance to scoop up over 150% in gains, and it looks like the wheel has only begun to turn. The stock closed above the 50DMA, and the next major resistance doesn’t seem to show up until we reach the 100DMA of .0479.

The RSI is heading toward the power zone, as the blue bars on the histogram are building up on the bullish side. We saw recent crossovers on both the PPO and the Slow STO; both indicators broke through their 50MA. We’d like to see future support hold at the 50DMA of .0184.

___

Extended Watchlist:

AMBS, DNYS, RENU, PERI, GTXI,

SAFC, PPHM, BTHR & Extended Watchlist

We wanted to bring SAFC to your attention this morning, as a number of factors is causing us to keep a watchful eye. The company recently announced a share buyback program for the month of January wherein 1,000,000 shares will be bought at up to $0.20 per share. We are also seeing a stock coming off of a recent bottom; on Friday it rose 15% on light volume. This often indicates a tightly-held, low-float play, upon which any surge of buying can act as a catalyst for much larger increases.

It is for those reasons that we kick off our week keeping an eye on SAFC.

___

Peregrine Pharmaceuticals, Inc. PPHM

We’ve seen a lot from PPHM in the roughly 5 months we’ve been monitoring the stock. With our first mention coming on August 14th, and focusing more intently in the weeks that followed, we saw PPHM rise from the 1.80’s all the way up to 5.50 on Sept. 21st. It was at that time we observed a huge sell-off, in fact the stock has been as low as .68 as recently as November.

___

Big Three Restaurants, Inc. BTHR

BTHR was as low as .0012 when it appeared on our watchlist on Wednesday. On Friday the stock closed at the high-of-day of .0022, for a gain of 83% in just two day’s time.

___

Extended Watchlist:

ABAT, AMBS, BMSN, MWIP, VSUT, STOA, FOLD

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:


Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.

___

We will be continuing to follow this play, and keep everyone updated as more details arise.

___

MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.

___

Extended Watchlist:

UNLA, AHFD, AXCG, SAPX, SFAZ, ZLCS

BMSN, AMBS & Extended Watchlist

Yesterday in reference to BMSN, we stated that “we are expecting to see a pullback at some point. In such an event, we’d like to see the support hold off of the 50DMA of .001.”  Sure enough, that’s exactly what we saw, as the stock bounced off of .0011 before closing at .0018. Not only did BMSN follow our prediction to the letter, but it managed a 64% intraday gain off of the bounce as well.Accumulation remains at an all-time high, with close to three-quarters of a million dollars changing hands yesterday, a record-setting volume day for the stock. This leads us to believe that there is certainly something left in the tank for BMSN, and we will continue to monitor the Level 2 as we do with every ticker that’s high on our watchlist, to make sure that support holds in the .001’s.

___

Amarantus Bioscience, Inc. AMBS

AMBS had another great day on Wednesday, raking in some more serious gains. We observed a new high of .195, on heavy momentum, much like BMSN. Yesterday was the third highest volume day the stock has logged in the past two months, with $4.5M in dollar volume. When we see momentum in a high-flyer like this, it’s easy to get excited, yet we remain vigilant. It’s important not to let greed run the table, and protect those profits where you can, after all, we’ve already seen cumulative gains of 1047% from AMBS.

___

Extended Watchlist:

PNCH, SNTL, UNLA, PRTN, EGCT, BGMD, DUSS

BMSN, AMBS, AAPL & Extended Watchlist

BMSN has been like a rocket lately, blasting off since we first alerted the stock back on December 26th.We have seen five consecutive days of gains, with Monday’s action breaking a previous resistance point of .0021 and reaching a high of ,0024, before closing at .0016.Considering the momentum we witnessed over the past five sessions, we are expecting to see a pullback at some point. In such an event, we’d like to see the support hold off of the 50DMA of .001.

Our next key level of resistance is going to be at .0024. If it can get past that, the next level is .003, and .004 (200DMA).

___

 

Amarantus Bioscience, Inc. AMBS

We first began talking about AMBS on November 6th. Another one on a serious uptrend; in the past 14 days of trading, the stock has seen just two days of closing in the red.

AMBS will be co-hosting an international symposium , the #C4CT Concussion Awareness Conference, “with the purpose of bringing thought leaders in the field of Traumatic Brain Injury (“TBI”) drug and diagnostic research & development, professional athletes, former professional athletes and celebrity sports figureheads that share the Company’s, TCMG’s and Brewer’s desire to support research into new TBI treatments, sports leagues who have social and fiduciary responsibilities to improve player safety and caring for former players previously affected by TBI and cognitive disorders, as well as other key stakeholders in the ongoing social discussion regarding head injuries and their side effects.”

BARCHART.COM currently has AMBS rated a “100% Buy”

We had stated before that we were looking for a break past .13, and that it would bring us into bluesky breakout mode, and now that it has done so, we’re going to hold onto our hats, because there’s no telling where it could stop. We’d like to see .13 hold as the new base level of support.

___

Apple, Inc. AAPL

AAPL was as low as 510.24 on Dec. 21st, and dipping as low as 504.66 on December 27th. With all of the hype coming from “fiscal cliff” negotiations, Monday’s big rally (closed at 532.1729) has the stock trading close to 550.00 premarket today.

___
Extended Watchlist:

 MSSD, BTHR, FORC, PPHM, MDIN, CTIX, SNTL, DNYS, KWK, NOK

Get Our FREE Daily Reports!

SUBSCRIBE